Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Dapagliflozin and Metformin Extended-Release Tablets 10/1000 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Yellow, oval, biconvex, extended-release film-coated tablet
Packaging
Box - 30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]
Approval status
Active

MFDS item code 202300423 · Approved 2023.01.31 · Insurance code 646005680

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment for whom monotherapy does not provide adequate glycemic control: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose of metformin as the patient was previously taking. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and dose adjustments made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the existing doses of dapagliflozin and metformin. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, with no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Since metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in controlling blood sugar
  • type 2 diabetes
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to help control blood sugar levels in adult patients with type 2 diabetes by combining dapagliflozin and metformin. It is mainly administered as an adjunct to diet and exercise to aid in blood sugar management. Particularly, for patients whose blood sugar is not well controlled and have cardiovascular disease or risk factors, further information regarding the cardiovascular effects of dapagliflozin can be referred to professionals. This medication is effective in improving blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment for whom monotherapy does not provide adequate glycemic control: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose of metformin as the patient was previously taking. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and dose adjustments made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the existing doses of dapagliflozin and metformin. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, with no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Since metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Precautions

This medication helps in controlling blood sugar levels. Before taking this medication, it is essential to confirm that kidney function is normal. It should not be used in patients with severely impaired kidney function. It should not be used in cases of severe infection, dehydration, decreased heart function, acute myocardial infarction, and patients undergoing surgery should stop this medication 48 hours before the procedure. Pregnant or breastfeeding women should not take this medication. This medication can cause hypoglycemia and caution is particularly warranted when used with insulin or other blood glucose-lowering agents, and other medication dosages may need adjustment as necessary. While taking this medication, watch out for symptoms of dehydration or low blood pressure and regularly check fluid status and blood pressure. A rare but serious side effect called lactic acidosis can occur, so if symptoms like malaise, muscle pain, difficulty breathing, or abdominal pain occur, notify a doctor immediately. Genital and urinary tract infections may occur; thus, prompt treatment is necessary if infection symptoms are present. This medication may lower vitamin B12 levels, so it is recommended to regularly check vitamin B12 levels with long-term use. Alcohol may increase the risk of side effects from this medication, so it is advised to avoid excessive drinking while on this medication. During the use of this medication, consistent monitoring of blood sugar control is crucial, especially for elderly patients or those with decreased kidney function. In case of overdose, seek appropriate treatment at a medical institution immediately, and dialysis may be beneficial if necessary. This medication is not recommended for children as safety and efficacy have not been established.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant lung neoplasm
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • altered sensation
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • tendonitis
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarthritis
  • tenosynovitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain the storage temperature between 1°C and 30°C to keep the medication effective for a longer time.

Appearance and packaging

Appearance

Yellow, oval, biconvex, extended-release film-coated tablet

Package unit

Box - 30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.